APA (7th ed.) Citation

ZR, Z., SL, L., T, Z., G, C., H, L., XD, S., . . . H, Y. (2024). Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): A single-arm, single-centre, phase 2 trial. The Lancet. Respiratory medicine, 12(12), 988. https://doi.org/10.1016/S2213-2600(24)00215-7

Chicago Style (17th ed.) Citation

ZR, Zhao, et al. "Stereotactic Body Radiotherapy with Sequential Tislelizumab and Chemotherapy as Neoadjuvant Therapy in Patients with Resectable Non-small-cell Lung Cancer in China (SACTION01): A Single-arm, Single-centre, Phase 2 Trial." The Lancet. Respiratory Medicine 12, no. 12 (2024): 988. https://doi.org/10.1016/S2213-2600(24)00215-7.

MLA (9th ed.) Citation

ZR, Zhao, et al. "Stereotactic Body Radiotherapy with Sequential Tislelizumab and Chemotherapy as Neoadjuvant Therapy in Patients with Resectable Non-small-cell Lung Cancer in China (SACTION01): A Single-arm, Single-centre, Phase 2 Trial." The Lancet. Respiratory Medicine, vol. 12, no. 12, 2024, p. 988, https://doi.org/10.1016/S2213-2600(24)00215-7.